Cargando…
A rebuttal to Akabayashi and colleagues’ criticisms of the iPSC stock project
In the October edition of the Journal of Medical Ethics, Akabayashi and colleagues state that ’to establish a heterogeneous [induced pluripotent stem cell] iPSC bank covering roughly 80% of Japan’s population…the Japanese government decided to invest JPY110 billion (US$ 1.1 billion) over 10 years in...
Autores principales: | Fujita, Misao, Tabuchi, Keiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691933/ https://www.ncbi.nlm.nih.gov/pubmed/30635361 http://dx.doi.org/10.1136/medethics-2018-105248 |
Ejemplares similares
-
Endangerment of the iPSC stock project in Japan: on the ethics of public funding policies
por: Akabayashi, Akira, et al.
Publicado: (2018) -
Affirming the need for a new model for the regulation of drug promotion: a rebuttal to Krause and Zettler
por: Bennett, Alan, et al.
Publicado: (2016) -
Response to Letter from Dr. Volbeda and Colleagues Regarding COVID-19 and CKD
por: Sörling, Annika, et al.
Publicado: (2023) -
Timing and Indications of Jones Tube Placement in Lacrimal Drainage System Malignancy Patients: A Rebuttal to the Letter by Shah et al [Response to Letter]
por: Kornhauser, Tom, et al.
Publicado: (2023) -
iPSC Bioprinting: Where are We at?
por: Romanazzo, Sara, et al.
Publicado: (2019)